Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06084819 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

StatusRecruiting
PhasePhase 2
Started2023-08-01
View on ClinicalTrials.gov ↗

Amendment history

2026-03-29
Study Status v1
Primary completion date2026-01-31→2029-01-31
Completion date2026-01-31→2030-01-31
2023-10-10
Original filing
The purpose of this study is to compare the efficacy and safety of venetoclax combined with CACAG regimen with BAT regimen in the treatment of relapsed/refractory acute myeloid leukemia.
Trial Details
NCT Number NCT06084819
Lead Sponsor Chinese PLA General Hospital
Collaborators: 940 Hospital of the People's Liberation Army Joint Logistic Support Force, The General Hospital of Western Theater Command, The General Hospital of Northern Theater Command, 960th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Air Force Military Medical University, China, Yantai Yuhuangding Hospital, People's Liberation Army (PLA) Strategic Support Force Characteristic Medical Center, First Hospital of China Medical University
Conditions Relapsed/Refractory Acute Myeloid Leukemia
Enrollment 200 participants
Start Date 2023-08-01
Primary Completion 2029-01-31 (estimated)
Study Completion 2030-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-02